Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723554 · ClinicalTrials.gov registry record · Phase 3
Iloprost Power Disc-15 in Pulmonary Arterial Hypertension
A Phase 3 study, sponsored by Actelion.
- Terminated
- Registry status
- Phase 3
- Development phase
- 63
- Enrollment target
NCT00723554 is a Phase 3 study that was terminated before completion, run by Actelion. The registered enrollment target is 63 participants.
The verdict
NCT00723554, a Phase 3 study, was terminated before completion, sponsored by Actelion.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 63 participants
- Enrollment target
Study Summary
A Phase IIIb, Multicenter, Open-Label Study of Patients With Pulmonary Arterial Hypertension Treated With Iloprost(Inhalation)Evaluating Safety and Inhalation Times When Converting From Power Disc-6 to Power Disc-15 With the I-neb® Adaptive Aerosol Delivery® System (I-neb® AAD®)
Interventions
- DRUG Iloprost PD-6
- DRUG Iloprost PD-15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00723554
The ClinicalTrials.gov registry entry for NCT00723554 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Iloprost PD-6 is the first listed.
NCT00723554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00723554 about?
NCT00723554 is a clinical study titled "Iloprost Power Disc-15 in Pulmonary Arterial Hypertension". A Phase IIIb, Multicenter, Open-Label Study of Patients With Pulmonary Arterial Hypertension Treated With Iloprost(Inhalation)Evaluating Safety and Inhalation Times When Converting From Power Disc-6 to Power Disc-15 With the I-neb® Adaptive Aerosol Delivery® System (I-neb® AAD®)
What is the current status of trial NCT00723554?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 63 participants. The study started on 2008-07. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00723554?
The interventions under investigation include: Iloprost PD-6 (DRUG), Iloprost PD-15 (DRUG).
Who is sponsoring clinical trial NCT00723554?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.